
Radar | Aug 08,2020
February 8 , 2020
By YOSEPH MERGU ( FORTUNE STAFF WRITER )
A pharmaceutical firm formed after a joint venture agreement between Ethiopian and Indian investors became the first company to launch construction of a plant in Kilinto Industrial Park.
Africure Pharmaceuticals Manufacturing Ethiopia Plc laid a cornerstone for the construction of the facility for 10 million dollars. Expected to be finalised within 18 months, the plant will occupy 12,000Sqm out of a total of 20,000Sqm of land designated for the company.
The Park, which was launched in 2018, was constructed for 5.5 billion Br on 279ha of land, has its power supply substitution system and zero liquid discharge water and chemical treatment facilities.
Once operational, the plant will make one billion tablets and capsules and 14 million bottles of syrup annually on its first phase of production. It is also expected to create 105 jobs, of which 95pc are for Ethiopians.
It will cover 65pc of the country’s pharmaceutical needs, according to Tadesse Teferi (MD), the Ethiopian shareholder of the company, which plans to launch the second phase to double production capacity and start making HIV medicines. The third phase, which is scheduled to take place in seven to 10 years, will produce active pharmaceutical ingredients (APIs).
Africure has plants in Cameroon, Namibia, Botswana and Cote d’Ivoire and are initiating the next facilities in Zimbabwe and Ethiopia.
Munir Kassa (MD), state minister for Health who attended the inauguration ceremony, explained that importing medicine for life-threatening diseases is tough.
“If investors build pharmaceutical manufacturing plants,” said Munir, “the Ministry will buy their products with good prices to incentivise them.”
Currently, up to 60pc of people die from infectious diseases and conditions related to child and mother care. More than 37pc die by non-communicable diseases such as cardiovascular diseases, diabetes, hepatic diseases and malaria.
Temesgen Tilahun, the deputy commissioner at the Ethiopian Investment Commission, attended the ceremony and stated that 12 additional pharmaceutical companies are expected to join the Park soon.
Eyasu Mekonnen (MD), associate professor and chair of the department of biochemistry and pharmacology under the College of Health Science at Addis Abeba University, says the plant arrived at a critical time.
People are dying from easily curable diseases, because of the chronic shortage of critical drugs, according to the pharmacologist.
“Currently, it’s becoming difficult to find medical drugs in the city,” says Eyasu. “It’s encouraging to find a pharmaceutical manufacturer constructing its own plant."
Eyasu also stressed that the company has to be regulated by the law, and it should have transparent manufacturing practices.
PUBLISHED ON
Feb 08,2020 [ VOL
20 , NO
1032]
Radar | Aug 08,2020
Fortune News | Sep 08,2019
Exclusive Interviews | Jan 22,2022
Radar | Oct 16,2021
Fortune News | Apr 16,2022
Fortune News | Oct 26,2019
Commentaries | Mar 06,2021
Fortune News | Aug 17,2019
Fortune News | Oct 03,2020
Radar | Apr 25,2020
November 27 , 2021
Against my will, I have witnessed the most terrible defeat of reason and the most sa...
November 13 , 2021
Plans and reality do not always gel. They rarely do in a fast-moving world. Every act...
October 16 , 2021 . By HAWI DADHI
Residing in a country with no capital market, an organised marketplace for trading se...
August 28 , 2021 . By HAWI DADHI
The streets of Addis Abeba are as varied as they are many, although too many of them have yet to be named. From the narrow alleyways of the...
June 25 , 2022
It is not the best of times to be in charge of governance in Ethiopia, whether at the...
June 18 , 2022
Some of Ethiopia's economic policymakers may take solace from realising that inflatio...
June 11 , 2022
The stereotype many people have of parliamentarians is as clueless seat fillers who exist to rubber stamp legislative bi...
June 4 , 2022
It was an institution confident in its mission, capabilities and progress that was on...
Put your comments here